Joanne Simpson

Joanne Simpson

Auto-generated profile, based on publicly available information

Joanne Simpson

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2019 in EMBO Reports
Verified
Journal Article
Open access
PDF file
JFJane Fraser
Jane Fraser
JSJoanne Simpson
Joanne Simpson
RFROSA FONTANA
ROSA FONTANA
CKChieko Kishi‐Itakura
Chieko Kishi‐Itakura
NKNicholas T Ktistakis
Nicholas T Ktistakis
NGNoor Gammoh
Noor Gammoh
Despite recently uncovered connections between autophagy and the endocytic pathway, the role of autophagy in regulating endosomal function remains incompletely understood. Here, we find that the ablation of autophagy‐essential players disrupts EGF‐induced endocytic trafficking of EGFR. Cells lacking ATG7 or ATG16L1 exhibit increased levels of phosphatidylinositol‐3‐phosphate (PI(3)P), a key determinant of early endosome maturation. Increased PI(3)P levels are associated with an accumulation of EEA1‐positive endosomes where EGFR trafficking is stalled. Aberrant early endosomes are recognised by the autophagy machinery in a TBK1‐ and Gal8‐dependent manner and are delivered to LAMP2‐positive lysosomes. Preventing this homeostatic regulation of early endosomes by autophagy reduces EGFR recycling to the plasma membrane and compromises downstream signalling and cell survival. Our findings uncover a novel role for the autophagy machinery in maintaining early endosome function and growth factor sensing.

12 December 2017 in Essays in Biochemistry
Verified
Journal Article
Open access
PDF file
JFJane Fraser
Jane Fraser
ACAinara G. Cabodevilla
Ainara G. Cabodevilla
JSJoanne Simpson
Joanne Simpson
NGNoor Gammoh
Noor Gammoh
Vesicular trafficking events play key roles in the compartmentalization and proper sorting of cellular components. These events have crucial roles in sensing external signals, regulating protein activities and stimulating cell growth or death decisions. Although mutations in vesicle trafficking players are not direct drivers of cellular transformation, their activities are important in facilitating oncogenic pathways. One such pathway is the sensing of external stimuli and signalling through receptor tyrosine kinases (RTKs). The regulation of RTK activity by the endocytic pathway has been extensively studied. Compelling recent studies have begun to highlight the association between autophagy and RTK signalling. The influence of this interplay on cellular status and its relevance in disease settings will be discussed here.

19 January 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KMKatherine Miles
Katherine Miles
JSJoanne Simpson
Joanne Simpson
SBSheila Brown
Sheila Brown
GCGraeme Cowan
Graeme Cowan
DGDavid Gray
David Gray
MGMohini Gray
Mohini Gray
The chronic autoimmune inflammatory diseases, systemic lupus erythematosus and Sjogren’s syndrome, develop when tolerance to apoptotic cells (ACs) is lost. We have previously reported that this tolerance is maintained by innate-like, IL-10 secreting regulatory B cells. Two questions remained. First, do these regulatory B cells belong predominantly to a single subset of steady-state B cells and second, what is their specificity? We report here that innate-like B cells with markers characteristic for B1a cells (CD43+veCD19hiCD5+veIgMhiIgDlo) constitute 80% of splenic and 96% of peritoneal B cells that respond to ACs by secreting IL-10. AC responsive B1a cells secrete self-reactive natural antibodies (NAbs) and IL-10, which is augmented by toll-like receptor (TLR) 7 or TLR9 stimulation. In so doing, they both accelerate the clearance of dying cells by macrophages and inhibit their potential to mount proinflammatory immune responses. While B1a cells make prolonged contact with ACs, they do not require TIM1 or complement to mediate their regulatory function. In an animal model of neural inflammation (experimental autoimmune encephalomyelitis), just 105 activated B1a B cells was sufficient to restrain inflammation. Activated B1a B cells also induced antigen-specific T cells to secrete IL-10. Hence, regulatory B1a cells specifically recognize and augment tolerance to apoptotic self via IL-10 and NAbs; but once activated, can also prevent autoimmune mediated inflammation.

2 September 2020 in Open Biology
Verified
Journal Article
Open access
JSJoanne E. Simpson
Joanne E. Simpson
NGNoor Gammoh
Noor Gammoh
Glioblastoma is the most common and aggressive adult brain tumour, with poor median survival and limited treatment options. Following surgical resection and chemotherapy, recurrence of the disease is inevitable. Genomic studies have identified key drivers of glioblastoma development, including amplifications of receptor tyrosine kinases, which drive tumour growth. To improve treatment, it is crucial to understand survival response processes in glioblastoma that fuel cell proliferation and promote resistance to treatment. One such process is autophagy, a catabolic pathway that delivers cellular components sequestered into vesicles for lysosomal degradation. Autophagy plays an important role in maintaining cellular homeostasis and is upregulated during stress conditions, such as limited nutrient and oxygen availability, and in response to anti-cancer therapy. Autophagy can also regulate pro-growth signalling and metabolic rewiring of cancer cells in order to support tumour growth. In this review, we will discuss our current understanding of how autophagy is implicated in glioblastoma development and survival. When appropriate, we will refer to findings derived from the role of autophagy in other cancer models and predict the outcome of manipulating autophagy during glioblastoma treatment.

14 December 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
JSJoanne Simpson
Joanne Simpson
KMKatherine Miles
Katherine Miles
MTMarta Trüb
Marta Trüb
RMRoisin MacMahon
Roisin MacMahon
MGMohini Gray
Mohini Gray
Plasmacytoid dendritic cells (pDCs) play a pivotal role in driving the autoimmune disease systemic lupus erythematosus, via the secretion of IFNα in response to nuclear self-antigens complexed with auto-antibodies. Apoptotic cells, generated at sites of inflammation or secondary lymphoid organs, are exposed to activated pDCs and also express the same nuclear antigens on their cell surface. Here we show, that in the absence of autoantibodies, activated pDCs respond to apoptotic cell expressed chromatin complexes by secreting IL-10 and IL-6, which also induces T cells to secrete IL-10. Conversely, when activated by the viral mimetic, CpGA, apoptotic cells enhance their secretion of IFNα. This study demonstrates, that activated pDCs respond directly to apoptotic cells and may maintain tolerance via IL-10, or promote inflammation through secretion of IFNα, depending on the inflammatory context.

3 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MPMichael Tc Poon
Michael Tc Poon
MBMorgan Bruce
Morgan Bruce
JSJoanne E Simpson
Joanne E Simpson
CHCathal John Hannan
Cathal John Hannan
PBPaul Brennan
Paul Brennan
Malignant glioma cell line models are integral to pre-clinical testing of novel potential therapies. Accurate prediction of likely efficacy in the clinic requires that these models are reliable and consistent. We assessed this by examining the reporting of experimental conditions and sensitivity to temozolomide in glioma cells lines. We searched Medline and Embase (Jan 1994-Jan 2021) for studies that evaluated the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line. Studies using a drug-resistant cell line or a modified preparation of temozolomide were excluded. Key data items included type of cell lines, temozolomide exposure duration, and cell viability measure (IC 50 ). We included 212 eligible studies from 2,789 non-duplicate records that reported 248 distinct cell lines. The commonest cell line was U87 (60.4%). Only 10.4% studies used a patient-derived cell line. The proportion of studies not reporting each experimental condition ranged from 8.0-27.4%, including base medium (8.0%), serum supplementation (9.9%) and number of replicates (27.4%). In studies reporting IC 50 the median value for U87 cell line at 24 hours, 48 hours and 72 hours was 123.9μM (IQR 75.3-277.7μM), 223.1μM (IQR 92.0-590.1μM) and 230.0μM (IQR 34.1-650.0μM), respectively (Figure 2A). The median IC 50 at 72 hours for patient-derived cell lines was 220μM (IQR 81.1-800.0μM). Temozolomide sensitivity reported in comparable studies was not consistent between and within individual malignant glioma cell lines. Drug discovery science performed on these models cannot reliably inform clinical translation. A consensus model of reporting can maximise reproducibility and consistency among in vitro studies. Key points: There is a wide variety of study designs for malignant glioma cell line studies. Reporting of experimental designs of cell line studies was suboptimal. Temozolomide sensitivity was inconsistent between and within individual cell lines. Importance of the study: There is a wide variety of experimental designs for malignant glioma cell line studies but the reporting of these is suboptimal. Temozolomide sensitivity reported in comparable studies was not consistent between and within individual malignant glioma cell lines. While there will be variations of opinion on what the optimal design is, a consensus model of a reporting structure is the only rational way to maximise the yield from in vitro studies to find novel therapies for our patients.